Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | BCL2A1 | Q16548 | 6/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.47 |
| ▸ | MAFG | O15525 | 1/20 | 0.45 |
| ▸ | PRKAR2A | P13861 | 1/20 | 0.43 |
| ▸ | PRKAR2B | P31323 | 1/20 | 0.43 |
| ▸ | KRAS | P01116 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20694360 | 0.98 | ESR1 (0.49) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL20694567 | 0.95 | ESR1 (0.53) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL24919560 | 0.94 | ESR1 (0.50) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL22802820 | 0.94 | ESR1 (0.50) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL24919561 | 0.94 | ESR1 (0.50) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL20694604 | 0.94 | ESR1 (0.52) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL24918851 | 0.93 | CTNNB1 (0.49) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL26421014 | 0.93 | CTNNB1 (0.49) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL26420998 | 0.91 | CTNNB1 (0.49) | ESR1ESR2ACE2BCL2A1MCL1 | |
| SCHEMBL22802822 | 0.90 | ESR1 (0.52) | ESR1ESR2ACE2BCL2A1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022246086-A1 | ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS | BIOHAVEN THERAPEUTICS LTD. (US) | 2022-11-24 | — | — | WO | disclosed |
| WO-2021102052-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021003050-A2 | CD38-BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2020132588-A1 | COMBINATION THERAPY OF ARMS AND NATURAL KILLER CELLS | KLEO PHARMACEUTICALS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2019023501-A1 | UNIVERSAL ABT COMPOUNDS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-01-31 | — | — | WO | disclosed |